Background The failure of conventional therapies and the propensity for recurrence and metastasis make triple-negative breast cancer (TNBC) a formidable challenge with grim prognoses and diminished survival rates. Immunotherapy. including immune checkpoint blockade and chimeric antigen receptor (CAR)-T cell therapy. presents innovative and potentially more effective strategies for add... https://www.roneverhart.com/Stardust-XLF/